A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

NCT03873532 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

298

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Surufatinib
DRUG: Capecitabine

Sponsor

Hutchison Medipharma Limited